IMPORTANCE Pulmonary hypertension (PH) is diagnosed by a mean pulmonary arterial pressure (mPAP) value of at least 25 mm Hg during right heart catheterization (RHC). While several studies have demonstrated increased mortality in patients with mPAP less than that threshold, little is known about the natural history of borderline PH. MAIN OUTCOME AND MEASURES Our primary outcome was all-cause mortality after adjusting for clinically relevant covariates in a Cox proportional hazards model. Our secondary outcome was the diagnosis of overt PH in patients initially diagnosed with borderline PH. Both outcomes were determined prior to data analysis. RESULTS 
P ulmonary hypertension (PH) is a highly morbid disease that develops from a primary pulmonary vasculopathy or secondary to chronic pulmonary, cardiac, or systemic illnesses. [1] [2] [3] Pulmonary hypertension is currently defined by a mean pulmonary arterial pressure (mPAP) value of at least 25 mm Hg on right heart catheterization (RHC), 1 a definition "empirically and arbitrarily" established by a consensus gathering of PH experts in 1973. 4 This mPAP threshold is not based on physiologic data; in fact, the mean (SD) mPAP in healthy patients is 14.0 (3.3) mm Hg, 5 suggesting an upper limit of normal significantly less than 25 mm Hg. Several investigators have evaluated the clinical characteristics and outcomes of patients with mPAP values less than the current diagnostic threshold of 25 mm Hg, referred to as borderline PH. [6] [7] [8] In the largest report to our knowledge to date, Maron et al 8 identified decreased adjusted survival in patients with borderline PH, defined as mPAP 19 to 24 mm Hg, in a large, multicentered Veterans Affairs cohort. 8 The generalizability of these data to the broader population is not known. Importantly, data on longitudinal RHC measurements in patients with borderline PH have not been reported. Establishing the clinical profile, prognosis, and natural history of patients with borderline PH identified within a diverse patient population has important ramifications on characterizing the spectrum of clinical risk associated with pulmonary arterial pressures in clinical practice.
Methods

Study Population
The Vanderbilt University institutional review board approved this study. All patients were identified through Vanderbilt's deidentified electronic health record, the Synthetic Derivative. 9, 10 The Vanderbilt Synthetic Derivative operates under a waiver of consent because all data are deidentified. Findings from this cohort have been previously reported, 11, 12 and additional details on patient exclusions and data acquisition are provided in the eMethods in the Supplement. Patients were categorized by mPAP values available on the RHC report. In the event an individual had undergone multiple RHCs, data from the first procedure were used in this analysis. Pulmonary hypertension was defined as an mPAP value of at least 25 mm Hg. 1 Although it does not have a consensus definition, borderline PH was defined as an mPAP value of 19 to 24 mm Hg for the purpose of this study according to published thresholds. 8 Accordingly, the reference group of patients was defined as having an mPAP value of 18 mm Hg or less. Precapillary and postcapillary PH were defined as PH with a pulmonary arterial wedge pressure (PAWP) of 15 mm Hg or less and greater than 15 mm Hg, respectively. The medical records of all patients meeting the hemodynamic definition of pulmonary arterial hypertension (PAH) and who were receiving PAH-specific therapies were manually reviewed to confirm the treating physician's diagnosis of PAH. 1 
Statistical Analyses
Data are expressed as median and quartiles for continuous variables and counts and percentages for categorical variables unless stated otherwise. Differences between 2 groups were assessed using the Mann-Whitney U or χ 2 test, as appropriate.
Repeated measurements of categorical and continuous variables for an individual were analyzed using McNemar test and paired t test, respectively. Two-tailed P values less than .05 were deemed significant. To account for missing data, we imputed 5 data sets for all regression analyses using multiple imputation with additive regression, bootstrapping, and predictive mean. 13 Additional imputation methods are found in the eMethods in the Supplement. Univariate and multivariate logistic regression were used to identify clinical variables associated with borderline PH in all patients without PH (mPAP less than 25 mm Hg). Unadjusted and adjusted survival were analyzed using the KaplanMeier and Cox proportional hazard methods after adjusting for 34 clinically relevant covariates selected a priori, respectively. We included restricted cubic splines with 4 knots for all continuous variables in our model, with significant nonlinear effects. Results are reported as odds ratio (OR) or hazard ratio (HR) of all-cause mortality, as appropriate, with 95% confidence intervals and P values. All tests of significance were 2-tailed, with statistical significance deemed to be at an α level of less than .05. We also present the HR of all-cause mortality associated with mPAP values within the range of 11 to 60 mm Hg, with mPAP values of 10 mm Hg serving as the reference group for this analysis. 8 To examine the prespecified effect modification by sex, race/ethnicity, heart failure type, and PH subtype, we performed analyses by including interaction terms between mPAP and these covariates in the Cox proportional hazards model for all patients. Additional analyses were performed after excluding patients with PAH and all patients with a pulmonary vascular resistance (PVR) greater than 3 Wood units. Statistical analysis was performed using R, version 3.3.1 (R Programming) and Stata for Macintosh, version 14.0 (StataCorp).
Results
Demographics and Clinical Characteristics
From 5797 unique patients referred for RHC (eFigure 1 in the Supplement), we identified 1454 patients who met the pre-
Key Points
Question How does the survival for patients with borderline pulmonary hypertension compare with those with lower mean pulmonary arterial pressures?
Findings In this cohort study of 4343 patients undergoing right heart catheterization at a large academic medical center, increased mortality was observed in patients with borderline pulmonary hypertension compared with reference patients after adjusting for clinically relevant covariates. Furthermore, patients with borderline pulmonary hypertension who underwent repeated catheterization often progressed to overt pulmonary hypertension.
Meaning
Patients with borderline pulmonary hypertension should be considered an at-risk subgroup with increased mortality compared with patients with lower mean pulmonary arterial pressures.
specified exclusion criteria. The remaining 4343 patients constituted the study cohort and were categorized further based on their mPAP values: 2684 (62%) with mPAP value of at least 25 mm Hg (PH), 783 (18%) with mPAP value 19 to 24 mm Hg (borderline PH), and 876 (20%) with mPAP value 18 mm Hg or less (reference group). Of the 2684 patients with PH, 1768 (66%) and 916 (37%) were classified as having postcapillary and precapillary PH, respectively. In total, 60% of the RHCs (n=2606) were performed on outpatients and two-thirds of RHCs were performed for coronary artery disease (25%; n = 1197), congestive heart failure (20%; n = 951), pulmonary hypertension (13%; n = 619), or aortic valve disease (9%; n =421; eTable 1 in the Supplement).
Patients with borderline PH were older with a higher prevalence of metabolic, vascular, cardiac, and pulmonary diseases compared with the reference group ( Table 1) . Diabetes, atrial fibrillation, obstructive sleep apnea, anemia, heart failure, and connective tissue disease were more prevalent in patients with PH. Brain natriuretic peptide, glomerular filtration rate, hemoglobin, and hemoglobin A 1C values in borderline PH were intermediate between PH and reference patients. Patients with borderline PH were more likely to be treated with anticoagulant, lipid-lowering, diuretic, and antihypertensive medications than patients in the reference group. Anticoagulant and diuretic use were highest in the PH group. 
Hemodynamic and Echocardiographic Data
The hemodynamic characteristics of the patient groups are presented in Table 2 . We observed a gradient in the severity of pulmonary hemodynamics across the reference, borderline PH, and overt PH groups including PVR, pulmonary arterial capacitance, and pulmonary arterial oxygen saturation. Cardiac function, as measured by stroke volume, cardiac output, and cardiac index, was similar between patients with borderline PH and reference patients, but all were lower compared with PH. Transthoracic echocardiography was performed in 4009 of 4343 patients (92%) within 6 months of RHC (median interval between RHC and echocardiography, 2 days; interquartile range [IQR] , 19 days prior to 1 day prior). We observed increased left ventricle (LV) remodeling in patients with borderline PH compared with reference patients based on higher LV mass index and a higher prevalence of LV hypertrophy and left atrial enlargement ( 
Outcomes
The unadjusted mortality was intermediate for borderline PH relative to overt PH and the reference group ( Figure 1) , with a 5-year survival of 83%, 75%, and 59% for reference patients, patients with borderline PH, and patients with overt PH, respectively. The difference in unadjusted 5-year survival for reference patients, patients with borderline PH, and patients with overt PH were similar after excluding patients treated with diuretics (90%, 80%, and 67%), treated with PAH-specific medi- cations (83%, 74%, and 59%), or with a PVR of greater than 3 Wood units (84%, 76%, and 63%). When patients with borderline PH were stratified into tertiles of PAWP (≤9 mm Hg, 10-13 mm Hg, and ≥14 mm Hg) the unadjusted 5-year survival was 60%, 74%, and 69%, respectively. After adjusting for 34 relevant covariates in a Cox proportional hazards model, the risk of all-cause mortality was higher for patients with PH (HR, 1.70; 95% CI, 1.37-2.10; P < .001) and patients with borderline PH (HR, 1.31; 95% CI, 1.04-1.65; P = .001) when compared with reference patients (eTable 3 in the Supplement, including the list of adjusted covariates). When mPAP was modeled as a continuous, nonlinear variable adjusting for the same covariates, the HR for death compared with a reference group (mPAP value, 10 mm Hg) increased immediately and incrementally starting from mPAP values of 11 mm Hg (HR, 1.08; 95% CI, 1.05-1.11; P < .001) through 60 mm Hg (HR, 4.87; 95% CI, 3.51-6.74; P < .001) ( Figure 2A ). For patients with borderline PH, the relative HR of death ranged from 1.95 (95% CI, 1.56-2.44; P < .001) at 19 mm Hg to 2.54 (95% CI, 1.91-3.39; P < .001) at 24 mm Hg. A similar relationship was observed when patients with PAH were excluded, although the magnitude of risk was lower. There was an incremental increase in the hazard of death associated witha1mmHghigher mPAP value in the entire range studied; however, the effect ofa1mmHghigher mPAP value was most pronounced in the reference and borderline PH range (eFigure 2 in the Supplement). In our model, sex significantly interacted with mPAP, such that women had a higher HR for death at a given mPAP compared with male patients ( Figure 2B ; β, −0.0131; P < .001). Because our population is enriched in patients with PAH who are predominantly women, we hypothesized that patients with PAH drove the sex interaction. However, when patients with were excluded from the analysis, the sex interaction remained (β, −0.0142; P = .001). No interaction was found between mPAP and our other prespecified analyses of heart failure subtype (preserved or reduced ejection fraction), race/ethnicity (white, black, or other), or PH subtype (precapillary or postcapillary PH). Receiver operator characteristic curve analyses for various mPAP cutoffs are reported in eFigure 3 in the Supplement, generally demonstrating that mPAP at any value is poorly discriminating in its ability to predict mortality.
Repeated Catheterization Data
We identified 70 patients initially diagnosed with borderline PH who underwent a repeated RHC (median interval between RHC, 35 weeks; IQR, 12-124 weeks). Compared with the 713 patients with borderline PH who did not undergo a repeated RHC, these patients were younger, with more advanced and prevalent cardiac disease, although were otherwise similar (eTable 4 in the Supplement). From this subgroup, 43 of 70 patients (61%) were subsequently diagnosed as having PH, 18 (26%) remained having borderline PH, and 9 (13%) had an mPAP value of 18 mm Hg or less ( Figure 3) . The median mPAP and PAWP increased by 5 mm Hg (IQR, 21-26 mm Hg) and 3 mm Hg (IQR, 13-16 mm Hg), respectively, in these patients (both P < .001), with 13 patients (19%) developing an mPAP of at least 35 mm Hg. The PVR and transpulmonary gradient (difference between mPAP and PAWP) also increased in patients diagnosed with PH on repeated RHC (eTable 4 in the Supplement). Of the patients diagnosed as having PH on subsequent RHC, 34 (79%) and 9 (21%) developed postcapillary PH and precapillary PH, respectively. The demographic, clinical, echocardiographic, and baseline hemodynamic characteristics between the 43 patients with borderline PH with a follow-up mPAP level of at least 25 mm Hg and the 27 patients with a follow-up mPAP level of 25 mm Hg or less were identical, even after adjusting for age and sex (eTable 5 in the Supplement). Unadjusted 5-year survival in the patients who developed PH was 62%, compared with 85% in those who did not (P = .008 by log-rank test).
Discussion
We aimed to determine the clinical correlates and prognostic effect of mPAP values less than the current diagnostic threshold for PH in a large and diverse referral population. We found that borderline PH is common in patients referred for RHC and associated with increased cardiopulmonary disease burden and mortality compared with lower mPAP values. The adjusted hazard of death increased incrementally and directly with a rise in mPAP, without an observed threshold. Finally, most patients (61%) with borderline PH who underwent a repeated RHC were subsequently diagnosed with overt PH, most commonly postcapillary PH. This study improves on prior work in this area by incorporating longitudinal mPAP measurements and statistical adjustments for LV function and medication exposures in a population enriched with women. Based on historical assumptions of the normal pressures within the pulmonary vasculature, PH has traditionally been defined by an mPAP value of at least 25 mm Hg. Critical appraisal of this threshold has been limited by a lack of data, and consequently, international PH guidelines have deferred comment on the clinical importance of mPAP values below this threshold.
14-16 While there is no universally accepted defini- Two limitations of these earlier studies are a lack of generalizability and use of cross-sectional analyses. We sought to validate and expand on these previous studies in our electronic health record-based cohort that is enriched with female patients, echocardiographic data, medication exposure, and longitudinal hemodynamic measurements. Compared with the VA CART study, our cohort was younger (median age, 61 years; IQR, 50-70 years vs 65 years; IQR, 60-73 years) and included a more balanced sex distribution (49% vs 3% women). Of note, with the exception of age and sex, the distribution of comorbidities was similar between the VA CART and our study.
After adjusting for numerous clinical covariates, we found that chronic obstructive pulmonary disease, left atrial diameter, and features of the metabolic syndrome were independently associated with a higher likelihood of borderline PH. Chronic hypoxia and left heart disease are the 2 most common causes of PH, 2,3 while higher hemoglobin A 1C and body mass index in borderline PH provide further evidence of an association between insulin resistance and pulmonary vascular disease. 12, [17] [18] [19] Although PAH and other PH phenotypes have fundamentally different etiologies, several studies have demonstrated that borderline PH exists on a spectrum between normal pulmonary hemodynamics and PAH in patients with scleroderma. [20] [21] [22] Our findings suggest that borderline PH is an early and intermediate pulmonary vascular phenotype in patients with exposure to numerous PH risk factors. The clinical profile of our cohort suggests most patients with borderline PH have existing or early left heart failure, rather than early PAH. Additional studies are needed to determine whether the mortality risk in patients with borderline PH can be modified, for example, by aggressive treatment of left heart disease and the attendant clinical risk factors. We observed increased mortality in patients with borderline PH when compared with reference patients. When we modeled the adjusted survival of patients at each mPAP compared with a reference value of 10 mm Hg, we did not observe a risk threshold at 19 mm Hg, as previously reported by Maron et al. 8 Rather, we saw an immediate and incremental increase in the hazard of death beginning at an mPAP of 11 mm Hg. There are several notable distinctions in our study population that may explain these different findings. The significantly higher proportion of patients who are younger, female, and have PAH in our cohort may have contributed to the difference, as suggested by a sex interaction with a higher HR among women at a given mPAP. Moreover, in contrast to the Follow-up right heart catheterization (RHC) data in 70 patients initially diagnosed with borderline PH demonstrated most (61%) develop overt PH, with a median increase in mPAP from 21 to 26 mm Hg (P < .001 by paired t test).
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VA CART study, our model included echocardiographic variables, medication exposure, and accounted for continuous values in a nonlinear fashion. Mortality in PH is generally attributed to right ventricular failure, and both our and the VA CART cohort demonstrated an increase in mortality at mPAP values currently considered normal. Despite our attempt to adjust for the complex medical illnesses in these patients, residual confounding may persist to explain in part the observed mortality differences. It remains unclear whether mild elevations of mPAP directly or indirectly contribute to the increased mortality in patients with borderline PH. Both experimental models of heart failure and human studies have demonstrated significant right ventricularpulmonary arterial uncoupling and right ventricular dyssynchrony in the borderline PH range, suggesting right ventricular dysfunction occurs with only mild increases in mPAP. 23, 24 While patients with mPAP values of 11 to 19 mm Hg likely have worse survival secondary to increased prevalence of comorbid illnesses, it is possible that subclinical decline in right ventricular function may contribute to mortality in these patients. However, preserved cardiac output and stroke volume suggest right ventricular dysfunction was not highly prevalent in the borderline PH group.
The continuous relationship between mPAP and mortality parallels other continuous physiologic measurements in humans, such as systemic blood pressure and cholesterol, which are independently associated with an increased risk of vascular complications and death. [25] [26] [27] [28] [29] These findings are potentially true for many other continuous variables that have somewhat arbitrary clinical thresholds. In the case of borderline PH, subtle elevations in mPAP reflect an increased burden of systemic disease. Mean pulmonary artery pressure is a surrogate that integrates the complex cardiopulmonary physiology of the patient. While mPAP is independently associated with mortality on a population level, it lacks sufficient discrimination to predict outcomes for an individual patient. A novel observation from our study is that many patients with borderline PH are diagnosed with overt PH on subsequent RHC. It is important to note that there is selection bias in patients who were referred for repeated RHC in our retrospective cohort. However, this finding warrants further inquiry in prospective studies. In the 70 patients with borderline PH (9%) who underwent repeated RHC, the conversion rate to overt PH was 61%, most of whom fell into the postcapillary PH phenotype. The median increase in mPAP for patients who developed PH was 10 mm Hg, with nearly 20% of all patients achieving an mPAP value greater than 35 mm Hg. Furthermore, most of these patients were undergoing repeated RHC within 1 year, suggesting a relatively rapid transition to overt PH in these patients. While PAWP increased along with mPAP in these patients, the PVR and transpulmonary gradient significantly increased as well. This suggests that decompensated heart failure with worsening volume status is not solely responsible for the progression to overt PH in these patients. Pulmonary vascular physiology is dynamic, and these findings highlight the limitations of static measurements in the evaluation of pulmonary vascular disease. Most patients with borderline PH who progressed to PH developed postcapillary physiology with relatively low PVR, suggesting that early PAH-directed therapy would not improve outcomes in these patients. The role of closer monitoring or intensification of treatments directed at the underlying causes of pulmonary or LV disease warrants further investigation.
Limitations
Our study has several limitations that should be considered when interpreting our findings. As we have addressed in previous reports of this cohort, 11, 12 this is a retrospective and singlecenter sample of an academic medical center spanning 17 years. Despite this limitation, our findings are generalizable to other referral populations given the large and heterogeneous nature of our sample. Although we are unable to manually review RHC tracings or echocardiographic images, we have demonstrated excellent agreement between hemodynamic and echocardiographic values derived by manual review and from the procedural reports. 11, 30 Given the technical challenges of obtaining accurate RHC measurements, some patient misclassification may have occurred in our cohort; however, this is likely to be modest on a population level and unlikely to be biased in a single direction. Finally, as addressed previously, there is confounding by indication in the repeated catheterization cohort because decompensating patients may be more likely to undergo repeated invasive testing than stable patients.
Conclusions
Borderline PH is common in patients referred for RHC at an academic tertiary referral center. These patients have a high comorbidity burden with increased mortality compared with patients with lower mPAP. Most patients with borderline PH who underwent repeated RHC developed overt PH. Subtle elevations of mPAP within a range currently considered normal were independently associated with mortality. This work builds on an evolving body of literature that suggests borderline PH is clinically important and reconsideration of the diagnostic classification of PH may be warranted. Future studies may consider evaluating the efficacy of closer interval monitoring or early therapeutic interventions, particularly in patients with left heart disease. 
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eMethods
Study population
We queried the Synthetic Derivative database, a de-identified mirror of the Vanderbilt electronic health record, for all right heart catheterization (RHC) reports between 1998 (when the catheterization reports became digitalized) and 2014. A unique algorithm based on regular expressions and pattern matching was developed to extract structured, quantitative data from all RHC reports. Both inpatients and outpatients were included in this study, but we excluded patients with values suggestive of decompensated physiology such as profound bradycardia, tachycardia, hypertension, or shock (1, 2) . Subjects with missing mean pulmonary arterial pressure or pulmonary arterial wedge pressure were also excluded. Data suggestive of entry error (e.g. arterial saturation > 100% or negative cardiac output) were deleted, and missing or deleted data were imputed for the purpose of all regression analyses (see Statistical Analysis for details).
Demographic and hemodynamic data were determined on the date of RHC. Hemodynamic variables were extracted from the RHC report, other than pulmonary arterial capacitance, which was calculated as the stroke volume (in mL) divided by the pulmonary arterial pulse pressure (in mmHg). When available, the cardiac output and index were calculated using the Fick method. Comorbidity, echocardiographic, and laboratory data were restricted to 6 months before or after RHC. We defined comorbidities based on ICD-9 coding or previously validated algorithms, as previously reported (1) (2) (3) . Quantitative and semi-quantitative echocardiographic data were extracted as described previously (2, 4) . We evaluated laboratory values that reflect disease severity (brain natriuretic peptide [BNP]) or co-morbid conditions (hemoglobin, glomerular filtration rate [GFR], hemoglobin A1c). We defined left ventricular (LV) hypertrophy and left atrial enlargement as LV posterior wall thickness ≥12mm and anterior-posterior left atrial diameter >40mm, respectively (5, 6) . Finally, medications were restricted to those included on the subject's medication list in the 6 months prior to RHC.
The Synthetic Derivative is linked to the Social Security Death Index, which was used to determine vital status. Follow-up time was calculated from the date of RHC. If death from any cause was reported to the Social Security Death Index, the reported date of death was recorded. Otherwise, patients were considered alive and were censored on the date of last Social Security Death Index search (June 1, 2016) .
Statistical analysis
We used the R function aregImpute to generate 5 imputed datasets, which is adequate when a moderate amount of data are missing 7 . The variables used for imputation are those presented in eTable 3, consistent with the recommendation that the imputation and analysis models should align 8 . Imputations were pooled by calculating the arithmetic mean of the estimates. Standard errors were generated from a formula combining between imputation and within-imputation variance 7 . Receiver Operator Characteristic curves for 1-year, 3-year and 5-year mortality were generated from logistic regression with mortality as the dependent variable and mPAP as the predictor. Sensitivity, specificity, positive predictive value and negative predictive value at mPAP levels from 12 to 31 were calculated based on the cross- 
